Engineered immune cells take on Hard-to-Treat liver cancer
NCT ID NCT06968195
First seen Nov 01, 2025 · Last updated May 22, 2026 · Updated 28 times
Summary
This early-stage trial tests a new treatment for people with advanced liver cancer that has not responded to standard therapies. The treatment uses the patient's own immune cells, modified in a lab to recognize and attack cancer cells carrying a specific protein called GPC3. The study aims to find the safest dose and see if this approach can shrink tumors or slow the disease.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED HEPATOCELLULAR CARCINOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Roswell Park Cancer Institute
Buffalo, New York, 14263, United States
Conditions
Explore the condition pages connected to this study.